Fig. 4

MCC950 inhibits the NLRP3 inflammasome pathway in DHBE. DHBE were infected with IAV at for 24 h (MOI = 2). A DHBE cells were treated with different concentrations of MCC950 for 24 h and cell survival was tested by MTT assay. Cells treated with DMSO only acted as control with cell viability set at 100%. The NLRP3 inflammasome components in DHBE were measured by qRT-PCR. B NLRP3, C ASC, D Caspase-1, E IL-1β, F IL-18 mRNA expression in DHBE. G The NLRP3 inflammasome components in DHBE was measured by western blot. H Normalized ratio of The NLRP3 inflammasome components to β-actin. (*denote P < 0.05, **denotes P < 0.01, ***denotes P < 0.001, significant difference between 0 and 5 nM; ^#denote P < 0.05, ^##denotes P < 0.01, ^###denotes P < 0.001, significant difference between 0 and 10 nM). Data are presented as the mean ± SD of three independent experiments